Lucid Diagnostics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
360 Madison Ave Fl 25, New York, New Yor...Phone Number
(888) 582-4339Website
www.luciddx.comRevenue
$5.4 MillionStock Symbol
LUCDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.Explore more
Lucid Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lucid Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Lucid Diagnostics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lucid Diagnostics
Check if Lucid Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Lucid Diagnostics is spiking on competitors!
Click to see if Lucid Diagnostics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Lucid Diagnostics launches new products
Lucid Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Lucid Diagnostics recently announced quarterly report
Recommended Actions
Find VP level buyers at Lucid Diagnostics
Find more new buyers
Compare Similar Companies to Lucid Diagnostics
Compare insights from companies similar to Lucid Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$40.1M
51-200
Private
-
2008
MM
Mariam MaghribiShifamed Chief Business Officer & President & CEO, Atia Vision & Tioga Cardiovascular
Company Profile Activity
Activity Insights
Lucid Diagnostics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lucid Diagnostics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lucid Diagnostics.
Lucid Diagnostics financials insights
Gather financial insights about Lucid Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$70M
2025
Stock Offering
$15.3M
Lucid Diagnostics Tech Stack
A closer look at the technologies used by Lucid Diagnostics
Most Recent Scoops
Earnings
reported that its sales team sold 2,770 EsoGuard tests in Q2 with a billable value of over $7.5 million, resulting in recognized revenue of $1.5 million. Revenue recognition for the majority of insurance claims is deferred under ASC 606 variable consideration guidelines until claims are collected, as the company remains in the transitional stages of its reimbursement process.
Earnings, Accounting, Sales, Financial Reporting, Finance
Earnings
reported Q2 non-GAAP operating expenses of $12.3 million, approximately 5% higher than Q1, reflecting increases in commercial activities including headcount, sales personnel, clinical service staff, and market access. The non-GAAP net loss per share for Q2 was $0.06, an improvement of approximately $0.01 sequentially and approximately $0.04 compared to each of the previous three quarters.
Hiring Plans, Spending/Investment, Sales, Clinical Operations
Earnings
Lucid Diagnostics has reported revenue of $1.5 million for Q2, reflecting an increase of approximately 17% compared to the prior quarter. The company performed 2,770 EsoGuard tests during the quarter, remaining within its target range of approximately 2,500 to 3,000 tests.
Earnings, Finance
Earnings
reported a cash balance of $33.4 million as of June 30, essentially flat with the year-end balance, following the completion of a common stock offering during Q2 with net proceeds of approximately $16.8 million. The average quarterly cash burn rate over the last four quarters, including cash interest on debt, was $11.6 million, with Q2 slightly lower at $11.3 million.
Earnings, Business Finance, Finance, Financing & Debt
Event
Product Marketing, Events, Training, Sales, Software, Safety, First Responder, Field Marketing, Operations
Lucid Diagnostics News & Media
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and...Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following...Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lucid Diagnostics
Sign Up For FreeTo access detailed company insights
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal... Read More
